Hepatology, June 1999, p. 1617-1623, Vol. 29, No.
6
HEPATOLOGY Concise
Review
The Risk of Surgery in Patients With Liver Disease
Lawrence S. Friedman
From the Gastrointestinal Unit (Medical Services), Massachusetts
General Hospital and the Department of Medicine, Harvard Medical
School, Boston, MA.
Because of the multiple functions of the liver synthesis of most serum
proteins, metabolism of nutrients and drugs, excretion and
detoxification of endogenous toxins and exogenous agents, and
filtering of portal venous blood assessing the risk of surgery in patients
with liver disease is a challenging endeavor. Any or all of the
functions of the liver may be impaired in patients with liver
disease.1,2 As a result, the pharmacokinetic parameters
of anesthetics, muscle relaxants, analgesics, and sedatives can be
affected by changes in binding to plasma proteins, detoxification,
and excretion; bleeding risk can be increased because of
coagulopathy; and susceptibility to infection can be increased
because of altered functioning of hepatic reticuloendothelial cells
and other changes in the immune system as well as portal
hypertension. Perhaps most importantly, a diseased liver is
particularly susceptible to the hemodynamic changes that accompany
surgery. On the other hand, operative risk is probably not
increased in the vast majority of patients with liver disease,
including most of those with chronic hepatitis C, in whom liver
function is preserved.
Mild elevations of serum aminotransferase, alkaline phosphatase,
or bilirubin levels are frequent after surgical procedures, whether
performed under general, spinal, or epidural anesthesia.3,4 In
patients without preexisting liver disease, these perturbations are
usually transient, of no clinical significance, and often
unnoticed. Clinically important hepatic dysfunction is more likely
to occur in patients with preexisting liver disease. This review
will consider the factors that contribute to perioperative hepatic
dysfunction and prediction of operative risk in patients with liver
disease undergoing surgery other than liver transplantation.
EFFECTS OF ANESTHESIA AND
SURGERY ON THE LIVER
Anesthesia causes a moderate reduction in hepatic arterial blood
flow and hepatic oxygen uptake; however, a clinical effect of these
changes on healthy volunteers has not been shown.3 In one study, the reduction in hepatic blood
flow during the first 30 minutes of anesthesia averaged 35%
among 42 patients without liver disease.5 Interestingly, liver blood flow returned to
baseline during surgery, a finding that raises the possibility that
either the initial hypoperfusion or reperfusion injury, or both,
may contribute to postoperative liver dysfunction when it occurs.
Moreover, patients with liver disease are more likely than patients
without liver disease to experience hepatic decompensation with
anesthesia.1
The volatile anesthetics halothane and enflurane reduce hepatic
arterial blood flow as a result of systemic vasodilatation and a
slightly negative inotropic effect.3,6,7 By
contrast, these effects are minimal with isoflurane, which may
actually increase hepatic arterial blood flow and is the preferred
anesthetic agent in patients with liver disease.8 Moreover, isoflurane, as well as the newer
haloalkanes desflurane and sevoflurane, undergo less hepatic
metabolism (0.2% in the case of isoflurane) than either halothane
(20%) or enflurane (2% to 4%), presumably accounting for a
correspondingly lower risk of immunoallergic drug-induced
hepatitis.3,9,10
Still, even the risk of halothane hepatitis is quite low at one in
35,000 exposures.11 Recently,
the mechanism of halothane hepatitis was proposed to involve immune
sensitization to trifluoroacetylated proteins formed by oxidative
metabolism of halothane by cytochrome P450 2E1 in genetically
predisposed individuals.9 Such
metabolism can be inhibited by prior administration of disulfuram.
Risk factors for halothane hepatitis include obesity, female
gender, multiple exposures to halothane, and a family history of
similar occurrences.
Hypercarbia initiates sympathetic stimulation of the splanchnic
vasculature, thereby decreasing portal blood flow, and should be
avoided in patients with liver disease. The pCO2 should
be maintained in the range of 35 to 40 mm Hg during
surgery.8
The actions of commonly used neuromuscular blocking agents may
be prolonged in patients with liver disease because of reduced
plasma pseudocholinesterase activity, decreased biliary excretion,
and an increase in the volume of distribution. Atracurium has been
recommended as the agent of choice in patients with liver disease
or biliary obstruction, because its metabolism does not depend on
the liver or kidneys.8 The long-acting
nondepolarizing muscle relaxant, doxacurium, is recommended for
prolonged surgical procedures including liver transplantation.12
Because of reduced hepatic blood flow, the metabolism of
morphine and meperidine may be decreased in patients with liver
disease and portal hypertension, in contrast to fentanyl or
sufentanyl, which are the preferred narcotic agents. Similarly, the
metabolism of the benzodiazepine sedatives, diazepam and
chlodiazepoxide, can be prolonged in patients with liver disease,
and oxazepam and lorazepam, which are eliminated by glucuronidation
without hepatic metabolism, are preferred.1 Like benzodiazepines, barbiturates, which do
not affect hepatic blood flow significantly, bind to -aminobutyric acid
receptors in the brain, can precipitate hepatic encephalopathy, and
must be used with caution in patients with liver disease. Although
the metabolism of thiopental is decreased in patients with
cirrhosis, plasma protein binding of thiopental is also decreased,
so that total body clearance of the drug is unaltered in
cirrhosis.13 Rare instances of
usually cholestatic hepatotoxicity caused by benzodiazepines or
barbiturates, including a syndrome of fever, hepatitis,
lymphadenopathy, eosinophilia, and dermatitis, are no more likely
in patients with liver disease than in those without liver
disease.14 Chlorpromazine has a more
depressant effect on the central nervous system in patients with
liver dysfunction than in healthy subjects.8
The nature of the surgical procedure itself may be the most
important determinant of postoperative hepatic dysfunction in
patients with liver disease.1 For
example, laparotomy leads to a greater reduction in hepatic
arterial blood flow than does extra-abdominal surgery, in part
because traction on the abdominal viscera may cause reflex systemic
hypotension as a result of dilatation of capacitance vessels.15,16 The greater the degree of hemorrhage with
surgery, the greater the fall in hepatic blood flow and chance of
ischemic injury to the liver.17 In
patients with cirrhosis and previous abdominal surgery, adhesions
around the liver can be highly vascular, leading to an increased
risk of intraoperative bleeding. Morbidity and mortality rates are
higher for emergent than elective surgery, and cholecystectomy,
gastric surgery, and colectomy are associated with particularly
high mortality rates in patients with decompensated cirrhosis.18-26 In the absence of ascites,
subtotal cholecystectomy or cholecystostomy may be preferable to
cholecystectomy in a patient with advanced cirrhosis and
cholecystitis.18,20 On the other hand, laparoscopic
cholecystectomy can be performed safely in selected patients with
well-compensated cirrhosis and no signs of portal hypertension.27
Limited experience suggests that cardiac surgery is associated
with a high operative mortality rate in patients with cirrhosis.28 In a retrospective review of
13 patients with predominantly alcoholic cirrhosis undergoing
often emergent coronary artery bypass grafting, valve replacement,
or both, Klemperer et al. reported a postoperative mortality rate
of 80% in those with Child's class B cirrhosis, but no mortality
among those with Child's class A cirrhosis.28 The high mortality rate was attributed to
a high risk of major postoperative infections and bleeding, rather
than cardiac dysfunction. Risk factors for hepatic decompensation
after cardiac surgery include the total time of cardiopulmonary
bypass, use of nonpulsatile as opposed to pulsatile cardiopulmonary
bypass, and need for perioperative pressor support.29 Cardiopulmonary bypass may particularly
aggravate the coagulopathy of liver disease by inducing platelet
dysfunction, fibrinolysis, and hypocalcemia.30 Patients with advanced cardiac fibrosis
undergoing tricuspid valve replacement are thought to be at
particular risk of postoperative liver failure if ligation of the
inferior vena cava leads to an increase in caval pressure.31,32 In patients with advanced cirrhosis and
cardiac disease, less invasive procedures such as angioplasty,
valvuloplasty, or novel myocardial revascularization techniques are
recommended.33 In rare instances,
cardiac surgery followed by liver transplantation has been
performed.29 Even more rarely, liver
transplantation has been undertaken before cardiac surgery in
patients with left ventricular dysfunction,30 but the risk of hemodynamic instability
resulting from reduced venous return and reperfusion of the graft
during liver transplantation makes this approach especially
hazardous.29
ESTIMATING OPERATIVE RISK IN PATIENTS WITH
LIVER DISEASE
Precise estimates of operative risk in patients with well
characterized liver disease are hard to come by. Most available
data derive from relatively small retrospective studies of
cirrhotic patients undergoing abdominal surgery. Few studies have
examined surgical risk in patients with acute viral, chronic, or
alcoholic hepatitis, and some of the available data actually
predate the availability of modern serological testing and
hepatobiliary imaging. Contraindications to elective surgery in
patients with liver disease are listed in table 1.
|
View
This table
|
table 1. Contraindications to
Elective Surgery in Patients With Liver Disease |
Hepatitis. Acute hepatitis
is considered to be a contraindication to elective surgery. This
recommendation is based on older studies in which operative
mortality rates of 9.5% to 13% were reported in icteric patients
who underwent laparotomy as part of a diagnostic evaluation that
led to a diagnosis of acute viral hepatitis; such patients do not
undergo diagnostic laparotomy nowadays.34,35 Elective surgery is also contraindicated
in patients with histological evidence of alcoholic hepatitis, in
whom mortality rates as high as 55% have been reported in patients
undergoing open liver biopsy36,37 or portosystemic shunt surgery.38-40
Chronic Hepatitis. In
patients with chronic hepatitis, surgical risk appears to correlate
with the clinical, biochemical, and histological severity of
disease. Elective surgery has been reported to be safe in patients
with asymptomatic mild chronic hepatitis (formerly chronic
persistent hepatitis),41 whereas
patients with symptomatic and histologically severe chronic
hepatitis have an increased surgical risk, particularly if hepatic
synthetic or excretory function is impaired, portal hypertension is
present, or bridging or multilobular necrosis is seen on liver
biopsy specimens.42,43 Moreover, patients with severe
histological activity have been reported to have a higher rate of
tumor recurrence after resection of hepatocellular carcinoma
compared with patients with mild inflammation.44
Fatty Liver and Nonalcoholic
Steatohepatitis. In contrast to alcoholic hepatitis,
alcoholic or nonalcoholic fatty liver does not appear to
contraindicate elective surgery, although a trend toward increased
mortality following hepatic resection has been reported for
patients with moderate to severe steatosis (>30% of hepatocytes
containing fat).45 In any event, a
period of abstinence from alcohol before surgery is advisable
because of the potential perioperative complications of alcoholism,
including alcohol withdrawal in the postoperative period,
enhancement of halothane hepatotoxicity by alcohol as shown in an
animal model,46,47 and the possibility of toxicity with
therapeutic doses of acetaminophen (often used for analgesia in the
postoperative period) in alcoholics.48
Cirrhosis, due presumably to nonalcoholic steatohepatitis, may
be found unexpectedly in up to 6% of patients undergoing gastric
bypass surgery for morbid obesity.49
Most surgeons do not view the discovery of subclinical cirrhosis at
surgery to be a contraindication to proceeding with gastric bypass
surgery despite a reported perioperative mortality rate of 4% in
this group of patients.49
Other Causes of Liver
Disease. In patients with autoimmune hepatitis in
remission, elective surgery is well tolerated in patients with
compensated liver disease, but perioperative administration of
"stress" doses of hydrocortisone is indicated in patients taking
prednisone. Patients with cirrhosis caused by hemochromatosis may
require monitoring of diabetes in the perioperative period and
should be evaluated carefully for the possibility of
cardiomyopathy, which increases surgical risk, as suggested by
recent experience with liver transplantation in patients with
hemochromatosis.50 In patients with
Wilson's disease, neuropsychiatric involvement may interfere with
the ability of the patient to provide informed consent, and surgery
may precipitate or aggravate neurological symptoms. Moreover,
D-penicillamine interferes with the cross-linking of collagen and
may impair wound healing, so the dose should be decreased in the
first 1 to 2 postoperative weeks.51,52
Cirrhosis. Most available
data on the risk of surgery in patients with liver disease pertain
to cirrhosis18-27,49,53-67 (table 2). A number
of retrospective studies have shown that perioperative mortality
and morbidity rates correlate well with the Child-Turcotte68 or Child-Pugh67,69 class of cirrhosis. In a review of
100 patients with predominantly alcohol-induced cirrhosis
undergoing abdominal surgery, Garrison et al.53 in 1984 reported perioperative
mortality rates of 10%, 31%, and 76% for patients classified as
Child's class A, B, and C, respectively. Among 52 parameters
assessed in a multivariate analysis, the Child classification was
the best predictor of surgical mortality and morbidity. In a
similar study by Mansour et al. in 1997,54 nearly identical results were described in
92 patients with cirrhosis (approximately 50% alcoholic and
50% nonalcoholic) undergoing abdominal surgery, with mortality
rates of 10%, 30%, and 82% in patients classified as Child's class
A, B, and C, respectively. These and other studies have also
observed increased surgical risk in patients undergoing emergent as
opposed to elective surgery; abdominal operations, particularly
biliary tract surgery; and hepatic resection (see below). Some
studies have not confirmed the predictive value of the Child
classification, in part because few Child's class C patients were
included, nor has any study validated the predictive value of the
Child's class prospectively.64,66
|
View
This table
|
table 2. Risk Factors for
Morbidity and Mortality in Patients With Cirrhosis Undergoing
Surgery |
Although there are no prospective studies showing improved
surgical outcome after preoperative interventions to improve
hepatic function, widely accepted guidelines are that elective
surgery is well tolerated in patients with Child's class A
cirrhosis, permissible with preoperative preparation in patients
with Child's class B cirrhosis (except those undergoing extensive
hepatic resection or cardiac surgery), and contraindicated in
patients with Child's class C cirrhosis.70 Quantitative assessment of liver function
with dynamic tests such as galactose elimination capacity,
aminopyrine breath testing, indocyanine green clearance, and the
rate of metabolism of lidocaine to monoethylglycinexylidide has
also been reported to predict perioperative morbidity and mortality
in patients with cirrhosis, but these tests have not been shown
convincingly to provide additional prognostic information over that
provided by the Child-Pugh classification, nor have they gained
widespread clinical acceptance.71
Although the Acute Physiology, Age, and Chronic Health Evaluation
System (APACHE III) has been shown to predict survival in cirrhotic
patients admitted to an intensive care unit, the system has not
been studied specifically in cirrhotic patients undergoing
surgery.72
Respiratory compromise in patients with liver disease may result
from the hepatopulmonary syndrome (chronic liver disease, increased
alveolar-arterial gradient while breathing room air, and evidence
of intrapulmonary vascular dilatation), restrictive lung disease
caused by ascites or pleural effusions, pulmonary hypertension, and
immune-mediated lung disease associated with autoimmune liver
diseases.73 Severe hypoxemia
(pO2 <60 mm Hg) associated with liver disease is
generally considered a relative contraindication to surgery (except
for liver transplantation in patients with hepatopulmonary
syndrome). Fortunately, severe hypoxemia is rare in patients with
liver disease.74 In a recent
multivariate analysis, a diagnosis of chronic obstructive lung
disease and surgery on the respiratory tract were identified as
risk factors for mortality in patients with cirrhosis undergoing
surgery.67 A higher-than-usual
concentration of oxygen during anesthesia is recommended in
patients with cirrhosis.8
RESECTION FOR HEPATOCELLULAR
CARCINOMA
Hepatocellular carcinoma is a well-established complication of
long-standing cirrhosis, with an estimated annual incidence of 3%
to 5%.75-77 In the past, cirrhosis
was considered to be a contraindication to resection of hepatic
tumors, with reported perioperative mortality rates as high as 50%.
With better patient selection (including earlier detection of
tumors), meticulous preoperative preparation, intensive
intraoperative and postoperative monitoring, and improved surgical
techniques, the perioperative mortality rate for hepatic resection
has decreased to 3% to 16%, although postoperative morbidity rates
are still as high as 60%, 5-year recurrence rates are as high as
100%, and 5-year survival rates are no higher than 50%.76-82 The Child's classification is still the
most widely used measure of operability, but studies have failed to
confirm its value in predicting morbidity and mortality, in part
because of selection bias and the small number of patients with
Child's class B and C cirrhosis studied.78
Although Child's class A patients tolerate hepatic resection
well, a recent study has suggested that up to 60% of patients with
Child's class A cirrhosis associated with portal hypertension, as
measured by a hepatic venous pressure gradient of >10 mm Hg,
experience hepatic decompensation (ascites, jaundice, or
encephalopathy) after hepatic resection for hepatocellular
carcinoma.83 Additional risk factors
for morbidity after hepatic resection include thoracotomy,
pulmonary disease, diabetes mellitus, malignancy, and complex
intrahepatic inflammatory disease. Alternative methods of
quantitating hepatic reserve, including quantitative liver function
tests, indocyanine green clearance, uptake of radiolabeled gold
colloid by Kupffer cells, liver scintigraphy using
technetium-99m-galactosyl human serum albumin, and measurement of
hepatic volume by computed tomography, have not gained wide
acceptance.78,84-86 The question of whether patients with
Child's class A cirrhosis and a small hepatocellular carcinoma
should undergo liver transplantation instead of resection remains
controversial.75-77,80,87 Cryosurgery has been used in patients with
hepatic neoplasms not amenable to surgical resection, such as those
with multiple lesions abutting on major blood vessels. Experience
with this technique is limited, but the complications are the same
as those for hepatic resection, including hemorrhage, abscess,
pleural effusion, bile leak, and hepatic failure.88
SURGERY IN PATIENTS WITH OBSTRUCTIVE
JAUNDICE
The perioperative mortality rate in patients with obstructive
jaundice has been reported to range from 8% to 28%.89-91 In a large retrospective study of
373 patients undergoing surgery for obstructive jaundice
before 1983, the perioperative mortality rate was 9.1%, and
multivariate analysis identified three predictors of postoperative
mortality: an initial hematocrit value less than 30%, an initial
serum bilirubin level greater than 200 µmol/L
(11 mg/dL), and a malignant cause of obstruction (e.g.,
pancreatic carcinoma or cholangiocarcinoma).90 When all three factors were present, the
mortality rate approached 60%, whereas when none was present, the
mortality rate was only 5%. Other preoperative predictors of poor
surgical outcome in these patients include azotemia,
hypoalbuminemia, and cholangitis89-94
(table 3). Perioperative complications in
patients with obstructive jaundice include infections, resulting in
part from bacterial colonization of the biliary tree, impaired
Kupffer cell function, defective neutrophil function, and a high
rate of endotoxemia, renal failure, stress ulceration, disseminated
intravascular coagulation, and wound dehiscence.95-98 Renal failure is particularly common,
with a mean reported frequency of 8%.99-101
|
View
This table
|
table 3. Risk Factors for
Operative Mortality in Patients With Obstructive Jaundice |
There is limited evidence that perioperative oral administration
of ursodeoxycholic acid or lactulose may prevent endotoxemia and
reduce the likelihood of postoperative complications.102-104 Perioperative administration of
broad-spectrum intravenous antibiotics reduces the frequency of
postoperative infections but not the perioperative mortality
rate.103 Intravenous administration
of mannitol has been advocated to protect against postoperative
renal failure, but maintenance of intravascular volume is probably
a more critical element in management.103,105 Aminoglycosides, which are nephrotoxic,
and nonsteroidal antiinflammatory drugs, which can precipitate
hepatorenal syndrome, should be avoided.106-108
Despite suggestions to the contrary on the basis of
retrospective studies, preoperative external biliary drainage via a
transhepatic approach has not been shown in prospective randomized
controlled studies to improve surgical morbidity or mortality in
patients with obstructive jaundice.109-112 Endoscopic biliary drainage, while
having the advantages of restoring enterohepatic circulation of
bile acids and avoiding the complications of percutaneous puncture,
also has not been shown to improve surgical mortality in patients
with a malignant cause of biliary obstruction.113 However, in patients with acute
cholangitis and choledocholithiasis, endoscopic decompression of
the obstructed bile duct, in combination with intravenous
antibiotics, is associated with lower mortality and morbidity rates
than surgical decompression.114-116
Although endoscopic sphincterotomy is associated with an increased
rate of complications in patients with cirrhosis,117 morbidity and mortality rates are low
even in patients with Child's class C cirrhosis when biliary
decompression is achieved.118
PREOPERATIVE EVALUATION AND POSTOPERATIVE
MONITORING
Whether otherwise healthy surgical candidates should be screened
for unsuspected abnormalities of liver function tests is
controversial; abnormalities will be detected in approximately
1 in 700 such individuals.119,120 On the other hand, evaluation of any
patient undergoing surgery should include careful history-taking to
identify risk factors for liver disease, including previous blood
transfusions, tattoos, illicit drug use, sexual promiscuity, a
family history of jaundice or liver disease, a history of jaundice
or fever after anesthesia, alcohol use, and a complete review of
current medications. Symptoms or findings on physical examination
suggestive of liver disease, including fatigue, pruritus, increased
abdominal girth, jaundice, palmar erythema, spider telangiectases,
splenomegaly, and gynecomastia and testicular atrophy in men,
should be evaluated.
In patients known to have liver disease, it is important to
identify the presence of jaundice, ascites, or encephalopathy, to
obtain a complete biochemical assessment of liver function, and, if
necessary, evaluate the patient for the cause of liver disease.
Coagulopathy, ascites, and encephalopathy may require specific
treatment before surgery. Repletion of vitamin K, infusions of
fresh frozen plasma to correct the prothrombin time to within
3 seconds of normal, and transfusions of platelets to maintain
a count of at least 100,000/mm3 are recommended.8 A prolonged bleeding time can also be
treated with diamino-8-D-arginine
vasopressin.121 In general, because
of the possibility of postoperative wound dehiscence and abdominal
wall herniation, ascites should be treated aggressively before
abdominal surgery; if necessary, the ascites can be drained
completely at laparotomy. Although there is no evidence that
prophylactic therapy to prevent encephalopathy is beneficial in
patients with liver disease, it is important to recognize overt
encephalopathy preoperatively, because of the high frequency of
conditions that precipitate or exacerbate encephalopathy in the
postoperative period, including constipation, alkalosis, use of
central nervous system depressants, hypoxia, sepsis, azotemia, and
gastrointestinal bleeding. Preoperative identification, evaluation,
and management of renal dysfunction are equally critical. Although
gastroesophageal varices that have bled should be treated in the
usual manner, there are no clear data to suggest that surgery leads
to an increased risk of variceal bleeding in the postoperative
period, although fluid overload should be avoided. In the cirrhotic
patient with malnutrition, there is limited evidence that
perioperative nutritional support may reduce the frequency of
postoperative complications and short-term mortality but does not
improve long-term survival after hepatic resection.122-124 Percutaneous gastrostomy is
contraindicated in patients with ascites and should generally be
avoided in patients with portal hypertension.
In the postoperative period, the patient with liver disease
should be observed closely for signs of hepatic decompensation,
including worsening of jaundice, encephalopathy, and ascites. The
prothrombin time and serum bilirubin level are probably the best
measures of hepatic function, although the serum bilirubin can be
expected to rise initially, particularly after complicated surgery,
multiple blood transfusions, excessive bleeding, hemodynamic
instability, or systemic infection. Renal function should be
monitored as well because of the risk of hepatorenal syndrome.
Serum glucose levels should be followed closely, because
hypoglycemia often accompanies postoperative liver failure.
Acknowledgment
The author thanks Jules L. Dienstag, M.D., for his critical
review of this manuscript and Luci Trumbull for expert secretarial
assistance.
FOOTNOTES
Received October 9, 1998; accepted April 15, 1999.
Address reprint requests to: Lawrence S. Friedman, M.D.,
Gastrointestinal Unit, Blake 456D, Massachusetts General Hospital,
Boston, MA 02114-2696. E-mail: friedman.lawrence@mgh.harvard.edu;
fax: 617-724-6832.
REFERENCES
| 1. |
Friedman LS, Maddrey WC. Surgery in the patient
with liver disease. Med Clin North Am 1987;71:453-476. |
| 2. |
Gholson CF, Provenza JM, Bacon BR. Hepatologic
considerations in patients with parenchymal liver disease
undergoing surgery. Am J Gastroenterol 1990;85:487-496. |
| 3. |
Strunin L. Anesthetic management of patients with
liver disease. In: Millward-Sadler GH, Wright R, Arthur MJP (eds).
Wright's Liver and Biliary Disease. London: Saunders,
1992:1381-1393. |
| 4. |
Clark RSJ, Doggart JR, Lavery T. Changes in liver
function after different types of surgery. Br J Anesth
1976;48:119-127. |
| 5. |
Cowan RE, Jackson BT, Grainger SL, Thompson RPH.
Effects of anesthetic agents and abdominal surgery on liver blood
flow. HEPATOLOGY 1991;14:1161-1166. |
| 6. |
Batchelder BM, Cooperman LH. Effects of
anesthetics on splanchnic circulation and metabolism. Surg Clin
North Am 1975;55:787-794. |
| 7. |
Ngai SH. Effects of anesthetics on various organs.
N Engl J Med 1980;302:564-566. |
| 8. |
Maze M. Anesthesia and the liver. In: Miller RD
(ed). Anesthesia, 4th ed.. Edinburgh: Churchill Livingstone,
1994:1969-1980. |
| 9. |
Kenna JG. Immunoallergic drug-induced hepatitis:
lessons from halothane. J Hepatol 1997;26(Suppl 1):5-12. |
| 10. |
Berghaus TM, Baron A, Geier A, Lamerz R,
Paumgartner G, Conzen P. Hepatotoxicity following desflurane
anesthesia. HEPATOLOGY 1999;29:613-614. |
| 11. |
Holt C, Csete M, Martin P. Hepatotoxicity of
anesthetics and other central nervous system drugs. Gastroenterol
Clin N Am 1995;24:853-874. |
| 12. |
Hunter JM. New neuromuscular blocking agents. N
Engl J Med 1995;332:1691-1699. |
| 13. |
Pandele G, Chaux F, Salvadori C, Farinotti M,
Duvaldestin P. Thiopental pharmacokinetics in patients with
cirrhosis. Anesthesiology 1983;59:123-126. |
| 14. |
Farrell GC. Drug-Induced Liver Disease. Edinburgh:
Churchill Livingstone, 1994. |
| 15. |
Gelman SI. Disturbances in hepatic blood flow
during anaesthesia and surgery. Arch Surg 1976;111:881-883. |
| 16. |
Torrance HB. Liver blood flow during operation on
the upper abdomen. J R Coll Surg Edinb 1957;2:216-228. |
| 17. |
Rosenberg PM, Friedman LS. The liver in
circulatory failure. In: Schiff ER, Sorrell MF, Maddrey WC (eds).
Schiff's Diseases of the Liver, 8th ed.. Philadelphia:
Lippincott-Raven, 1999:1215-1227. |
| 18. |
Bloch RS, Allaben RD, Walt AJ. Cholecystectomy in
patients with cirrhosis: a surgical challenge. Arch Surg
1985;120:669-672. |
| 19. |
Aranha GV, Sontag SI, Greenlee HB. Cholecystectomy
in cirrhotic patients: a formidable operation. Am J Surg
1982;143:55-60. |
| 20. |
Aranha GV, Kruss D, Greenlee HB. Therapeutic
options for biliary tract disease in advanced cirrhosis. Am J Surg
1988;155:374-377. |
| 21. |
Castaing D, Houssin D, Lemoine J, Bismuth H.
Surgical management of gallstones in cirrhotic patients. Am J Surg
1983;146:310-312. |
| 22. |
Schwartz SI. Biliary tract surgery and cirrhosis:
a critical combination. Surgery 1981;90:577-583. |
| 23. |
McSherry CK, Glenn F. The incidence and causes of
death following surgery for non-malignant biliary tract disease.
Ann Surg 1980;191:271-275. |
| 24. |
Pitt HA, Cameron JL, Postier RG, Gadacz TR.
Factors affecting mortality in biliary tract surgery. Am J Surg
1981;141:66-72. |
| 25. |
Lehnert T, Herfarth C. Peptic ulcer surgery in
patients with liver cirrhosis. Ann Surg 1993;217:338-346. |
| 26. |
Metcalf AMT, Dozois RR, Wolff BG, Beart RW. The
surgical risk of colectomy in patients with cirrhosis. Dis Col Rect
1987;30:529-531. |
| 27. |
Sleeman D, Namias N, Levi D, Ward FC, Vozenilek J,
Silva R, Levi JU, et al. Laparoscopic cholecystectomy in cirrhotic
patients. J Am Coll Surg 1998;187:400-403. |
| 28. |
Klemperer JD, Ko W, Connolly M, Rosengart TK,
Altorki NK, Lang S, et al. Cardiac operations in patients with
cirrhosis. Ann Thorac Surg 1998;65:85-87. |
| 29. |
Morris JJ, Hellman CL, Gawey BJ, Ramsay MA, Valek
TR, Gunning TC, Suvgert TH, et al. Three patients requiring both
coronary artery bypass surgery and orthotopic liver
transplantation. J Cardiothorac Vasc Anesth 1995;9:322-332. |
| 30. |
Pollard RJ, Sidi A, Gibby GL. Aortic stenosis with
end-stage liver disease: prioritizing surgical and anesthetic
therapies. J Clin Anesth 1998;10:253-261. |
| 31. |
Kay JH. Surgical treatment of tricuspid
regurgitation. Ann Thorac Surg 1992;53:1132-1133. |
| 32. |
Toyoda Y, Okada M, Sugimoto T, Yoshida M, Ataka K,
Yamashita C. Successful treatment of cardiac cirrhosis: tricuspid
surgery and plasma exchange. J Cardiovasc Surg
1996;37:305-307. |
| 33. |
Gaudino M, Santarelli P, Bruno P, Piancone FL,
Possati G. Palliative coronary artery surgery in patients with
severe noncardiac diseases. Am J Cardiol 1997;80:1351-1352. |
| 34. |
Harville DD, Summerskill WHJ. Surgery in acute
hepatitis. JAMA 1963;184:257-261. |
| 35. |
Powell-Jackson P, Greenway B, Williams R. Adverse
effects of exploratory laparotomy in patients with unsuspected
liver disease. Br J Surg 1982;69:449-451. |
| 36. |
Greenwood SM, Leffler CT, Minkowitz S. The
increased mortality rate of open liver biopsy in alcoholic
hepatitis. Surg Gyn Obstet 1972;134:600-604. |
| 37. |
Kern WH, Mikkelsen WP, Turrill FL. The
significance of hyaline necrosis in liver biopsies. Surg Gyn Obstet
1969;129:749-754. |
| 38. |
Mikkelsen WP. Therapeutic portacaval shunt.
Preliminary data on controlled trial and morbid effects of acute
hyaline necrosis. Arch Surg 1974;108:302-305. |
| 39. |
Mikkelsen WP, Kern WH. The influence of acute
hyaline necrosis on survival after emergency and elective
portacaval shunt. Major Prob Clin Surg 1974;14:233-242. |
| 40. |
Mikkelsen WP, Turrill FL, Kern WH. Acute hyaline
necrosis of the liver: a surgical trap. Am J Surg
1968;116:266-272. |
| 41. |
Runyon BA. Surgical procedures are well tolerated
by patients with asymptomatic chronic hepatitis. J Clin
Gastroenterol 1986;8:542-544. |
| 42. |
Hargrove MD. Chronic active hepatitis: possible
adverse effect of exploratory laparotomy. Surgery
1970;68:771-773. |
| 43. |
Higashi H, Matsumata T, Adachi E, Taketomi A,
Kashiwagi S, Sugimachi K. Influence of viral hepatitis status on
operative morbidity and mortality in patients with primary
hepatocellular carcinoma. Br J Surg 1994;81:1342-1345. |
| 44. |
Ko S, Nakajima Y, Kanehiro H, Hisanaga M, Aomatsu
Y, Kin T, Yagura K, et al. Significant influence of accompanying
chronic hepatitis status on recurrence of hepatocellular carcinoma
after hepatectomy: result of multivariate analysis. Ann Surg
1996;224:591-595. |
| 45. |
Behrns K, Tsiotos GG, DeSouza NF, Krisha MK,
Ludwig J, Nagorney DM. Hepatic steatosis as a potential risk factor
for major hepatic resection. J Gastrointest Surg
1998;2:292-298. |
| 46. |
Takagi T, Ishii H, Takahashi H, Kato S, Okuno F,
Ebihara Y, Yamauchi H, et al. Potentiation of halothane
hepatotoxicity by chronic ethanol administration in rat: an animal
model of halothane hepatitis. Pharm Biochem Behav 1983;18(Suppl
1):461-465. |
| 47. |
Zimmerman HJ. Effects of alcohol on other
hepatotoxins. Alcoholism: Clin Exp Res 1986;10:3-15. |
| 48. |
Zimmerman HJ, Maddrey WC. Acetaminophen
(paracetamol) hepatotoxicity with regular intake of alcohol:
analysis of instances of therapeutic misadventure. HEPATOLOGY 1995;22:767-773. |
| 49. |
Brolin RE, Bradley LJ, Taliwal RV. Unsuspected
cirrhosis discovered during elective obesity operations. Arch Surg
1998;133:84-88. |
| 50. |
Farrell FJ, Nguyen M, Woodley S, Imperial JC,
Garcia-Kennedy R, Man K, Esquivel CO, et al. Outcome of liver
transplantation in patients with hemochromatosis. HEPATOLOGY 1994;20:404-410. |
| 51. |
Scheinberg IH, Sternlieb I. Wilson's disease. In:
Smith LH (ed). Major Problems in Internal Medicine, vol 23
Philadelphia: Saunders, 1984:150-151. |
| 52. |
Yarze JC, Martin P, Muñoz SJ, Friedman LS.
Wilson's disease: current status. Am J Med 1992;92:643-654. |
| 53. |
Garrison RN, Cryer HM, Howard DA, Polk HC Jr.
Clarification of risk factors for abdominal operations in patients
with hepatic cirrhosis. Ann Surg 1984;199:648-655. |
| 54. |
Mansour A, Watson W, Shayani V, Pickleman J.
Abdominal operations in patients with cirrhosis: still a major
surgical challenge. Surgery 1997;122:730-736. |
| 55. |
Doberneck RC, Sterling WA Jr, Allison DC.
Morbidity and mortality after operation in nonbleeding cirrhotic
patients. Am J Surg 1983;146:306-309. |
| 56. |
Kogut K, Aragoni T, Ackerman NB. Cholecystectomy
in patients with mild cirrhosis: a more favorable situation. Arch
Surg 1985;120:1310-1311. |
| 57. |
Aranha GV, Greenlee HB. Intra-abdominal surgery in
patients with advanced cirrhosis. Arch Surg 1986;121:275-277. |
| 58. |
Sirinek KR, Burk RR, Brown M, Levine BA. Improving
survival in patients with cirrhosis undergoing major abdominal
operations. Arch Surg 1987;122:271-273. |
| 59. |
Pearl RH, Clowes GHA, Bosari S, McDermott WV,
Menzoian JO, Love W, Jenkins RL. Amino acid clearance in cirrhosis:
a predictor of postoperative morbidity and mortality. Arch Surg
1987;122:468-473. |
| 60. |
Wong R, Rappaport W, Witte C, Hunter G, Jaffe P,
Hall K, Witzke D. Risk of nonshunt abdominal operation in the
patient with cirrhosis. J Am Coll Surg 1994;179:412-416. |
| 61. |
Leonetti JP, Aranha GV, Wilkinson WA, Stanley M,
Greenlee HB. Umbilical herniorrhaphy in cirrhotic patients. Arch
Surg 1984;119:442-445. |
| 62. |
Wirthlin LR, Van Urk H, Malt RB, Malt RA.
Predictors of surgical mortality in patients with cirrhosis and
nonvariceal gastroduodenal bleeding. Surg Gyn Obstet
1974;139:65-68. |
| 63. |
Lindenmuth WW, Eisenberg MM. The surgical risk in
cirrhosis of the liver. Arch Surg 1963;86:77-84. |
| 64. |
Gill RA, Goodman MW, Golfus GR, Onstad GR, Bubrick
MR. Aminopyrine breath test predicts surgical risk for patients
with liver disease. Ann Surg 1983;198:702-704. |
| 65. |
Rikkers LF. The changing spectrum of treatment for
variceal bleeding. Ann Surg 1998;228:536-546. |
| 66. |
Rice HE, O'Keefe GE, Helton WS, Johansen K. Morbid
prognostic features in patients with chronic liver failure
undergoing nonhepatic surgery. Arch Surg 1997;132:880-885. |
| 67. |
Ziser A, Plevak DJ, Wiesner RH, Rakela J, Offord
KP, Brown DL. Morbidity and mortality in cirrhotic patients
undergoing anesthesia and surgery. Anesthesiology
1999;90:42-53. |
| 68. |
Child CG, Turcotte JG. Surgery and portal
hypertension. In: Child CG (ed). The Liver and Portal Hypertension.
Philadelphia: Saunders, 1964:50-52. |
| 69. |
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC,
Williams R. Transection of the oesophagus for bleeding oesophageal
varices. Br J Surg 1973;60:646-649. |
| 70. |
Stone HH. Preoperative and postoperative care.
Surg Clin North Am 1977;57:409-419. |
| 71. |
Friedman LS, Martin P, Muñoz SJ. Liver
function tests and the objective evaluation of the patient with
liver disease. In: Zakim D, Boyer TD (eds). Hepatology: A Textbook
of Liver Disease, 3rd ed.. Philadelphia: Saunders,
1996:791-833. |
| 72. |
Zimmerman JE, Wagner DP, Seneff MG, Becker RB, Sun
X, Knaus WA. Intensive care unit admissions with cirrhosis:
risk-stratifying patient groups and predicting individual survival.
HEPATOLOGY 1996;23:1393-1401. |
| 73. |
King PD, Rumbaut R, Sanchez C. Pulmonary
manifestations of chronic liver disease. Dig Dis
1996;14:73-82. |
| 74. |
Moller S, Hillingso J, Christensen E, Henriksen
JH. Arterial hypoxaemia in cirrhosis: fact or fiction? Gut
1998;42:868-874. |
| 75. |
Akriviadis EA, Llovet JM, Efremidis SC, Shouval D,
Canelo R, Ringe B, Meyers WC. Hepatocellular carcinoma. Br J Surg
1998;85:1319-1331. |
| 76. |
DiBisceglie AM, Carithers RL Jr, Gores GJ.
Hepatocellular carcinoma. HEPATOLOGY
1998;28:1161-1165. |
| 77. |
Mor E, Kaspa RT, Sheiner P, Schwartz M. Treatment
of hepatocellular carcinoma associated with cirrhosis in the era of
liver transplantation. Ann Intern Med 1998;129:643-653. |
| 78. |
MacIntosh EL, Minuk GY. Hepatic resection in
patients with cirrhosis and hepatocellular carcinoma. Surg Gyn Obst
1992;174:245-254. |
| 79. |
Wu C-C, Ho W-L, Yeh D-C, Huang C-R, Liu T-J, P'eng
F-K. Hepatic resection of hepatocellular carcinoma in cirrhotic
livers: is it unjustified in impaired liver function? Surgery
1996;120:34-39. |
| 80. |
Bruix J. Treatment of hepatocellular carcinoma.
HEPATOLOGY 1997;25:259-262. |
| 81. |
Capussotti L, Polastri R. Operative risks of major
hepatic resections. Hepatogastroenterology 1998;45:184-190. |
| 82. |
Cohnert TU, Rau HG, Buttler E, Hernandez-Richter
T, Sauter G, Reuter C, Schildberg FW. Preoperative risk assessment
of hepatic resection for malignant disease. World J Surg
1997;21:396-400. |
| 83. |
Bruix J, Castells A, Bosch J, Feu F, Fuster J,
Garcia-Pagan JC, Visa J, et al. Surgical resection of
hepatocellular carcinoma in cirrhotic patients: prognostic value of
preoperative portal pressure. Gastroenterology
1996;111:1018-1022. |
| 84. |
Lau H, Man K, Fan S-T, Yu C, Lo C-M, Wong J.
Evaluation of preoperative hepatic function in patients with
hepatocellular carcinoma undergoing hepatectomy. Br J Surg
1997;84:1255-1259. |
| 85. |
Kim Y-K, Nakano H, Yamaguchi M, Kumada K, Takeuchi
S, Kitamura N, Takahashi W, et al. Prediction of postoperative
decompensated liver function by technetium-99m galactosyl-human
serum albumin liver scintigraphy in patients with hepatocellular
carcinoma complicating chronic liver disease. Br J Surg
1997;84:793-796. |
| 86. |
Kwon A-H, Ha-Kawa SK, Uetsuji S, Inoue T, Matsui
Y, Kamiyama Y. Preoperative determination of the surgical procedure
for hepatectomy using technetium-99m-galactosyl human serum albumin
(99mTc-GSA) liver scintigraphy. HEPATOLOGY 1997;25:426-429. |
| 87. |
Dmitrewski J, El-Gazzaz G, McMaster P.
Hepatocellular cancer: resection or transplantation. J
Hepatobiliary Panc Surg 1998;5:18-23. |
| 88. |
Sarantou T, Bilchik A, Ramming KP. Complications
of hepatic cryosurgery. Semin Surg Oncol 1998;14:156-162. |
| 89. |
Shirahatti RG, Alphonso N, Joshi RM, Prasad KV,
Wagle PK. Palliative surgery in malignant obstructive jaundice:
prognostic indicators of early mortality. J R Coll Surg Edinb
1997;42:238-243. |
| 90. |
Dixon JM, Armstrong CP, Duffy SW, Davies GC.
Factors affecting morbidity and mortality after surgery for
obstructive jaundice: a review of 373 patients. Gut
1983;24:845-852. |
| 91. |
Grieg JD, Krukowski ZH, Matheson NA. Surgical
morbidity and mortality in one hundred and twenty nine patients
with obstructive jaundice. Br J Surg 1988;75:216-219. |
| 92. |
Pain JA, Cahill CJ, Bailey ME. Perioperative
complications in obstructive jaundice: therapeutic considerations.
Br J Surg 1985;72:942-945. |
| 93. |
Blamey SL, Fearon KCH, Gilmour WH, Osborne DH,
Carter DC. Prediction of risk in biliary surgery. Br J Surg
1983;70:535-538. |
| 94. |
Lai ECS, Chu KM, Lo C-Y, et al. Surgery for
malignant obstructive jaundice: analysis of mortality. Surgery
1992;112:891-896. |
| 95. |
Greve JW, Gouma DJ, Soeters PB, Buurman WA.
Suppression of cellular immunity in obstructive jaundice is caused
by endotoxins: a study with germ-free rats. Gastroenterology
1990;98:478-485. |
| 96. |
Plusa S, Webster N, Primrose J. Obstructive
jaundice causes reduced expression of polymorphonuclear leucocyte
adhesion molecules and a depressed response to bacterial wall
products in vitro. Gut 1996;38:784-787. |
| 97. |
Wait RB, Kahng KU. Renal failure complicating
obstructive jaundice. Am J Surg 1989;157:256-263. |
| 98. |
Grande L, Garcia-Valdecasa JC, Fuster J, Visa J,
Pera C. Obstructive jaundice and wound healing. Br J Surg
1990;77:440-442. |
| 99. |
Fogarty BJ, Parks RW, Rowlands BJ, Diamond T.
Renal dysfunction in obstructive jaundice. Br J Surg
1995;82:877-884. |
| 100. |
Wait RB, Kahng KU. Renal failure in obstructive
jaundice. Am J Surg 1989;157:256-263. |
| 101. |
Kimmings AN, van Deventer SJH, Obertop H, Rauws
EAJ, Gouma DJ. Inflammatory and immunologic effects of obstructive
jaundice: pathogenesis and treatment. J Am Coll Surg
1995;181:567-581. |
| 102. |
Pain JA, Cahill CJ, Gilbert JM, Johnson CD,
Trapnell JE, Bailey ME. Prevention of postoperative renal
dysfunction in patients with obstructive jaundice: a multicentre
study of bile salts and lactulose. Br J Surg 1991;78:467-469. |
| 103. |
Diamond T, Parks RW. Perioperative management of
obstructive jaundice. Br J Surg 1997;84:147-149. |
| 104. |
Greve JW, Gouma DJ, van Leeuwen PAM, Buurman WA.
Lactulose inhibits endotoxin induced tumour necrosis factor
production by monocytes: an in vitro study. Gut
1990;31:198-203. |
| 105. |
Gubern JM, Sancho JJ, Simo J, Sitges-Serra A. A
randomized trial on the effect of mannitol on postoperative renal
function in patients with obstructive jaundice. Surgery
1988;103:39-44. |
| 106. |
Moore RD, Smith CR, Lietman PS. Increased risk of
renal dysfunction due to interaction of liver disease and
aminoglycosides. Am J Med 1986;80:1093-1097. |
| 107. |
Lucena MI, Andrade RJ, Cabello MR, Hidalgo R,
Gonzalez-Correa JA, Sanchez de la Cuesta F.
Aminoglycoside-associated nephrotoxicity in extrahepatic
obstructive jaundice. J Hepatol 1995;22:189-196. |
| 108. |
Gentilini P. Cirrhosis, renal function, and
NSAIDs. J Hepatol 1993;19:200-203. |
| 109. |
Hatfield ARW, Tobias R, Terblanche J, Fataar S,
Harries-Jones R, Kernoff L, et al. Pre-operative external biliary
drainage in obstructive jaundice: a prospective controlled trial.
Lancet 1982;ii:896-899. |
| 110. |
McPherson GAD, Benjamin IS, Hodgson HJF, Bowley
NB, Allison DJ, Blumgart LH. Pre-operative percutaneous
transhepatic biliary drainage: the results of a controlled trial.
Br J Surg 1984;71:371-375. |
| 111. |
Pitt HA, Gomes AS, Lois JF, Mann LL, Deutsch LS,
Longmire WP Jr. Does preoperative percutaneous biliary drainage
reduce operative risk or increase hospital cost? Ann Surg
1985;210:545-553. |
| 112. |
Clements WDB, Diamond T, McCrory DC, Rowlands BJ.
Biliary drainage in obstructive jaundice: experimental and clinical
aspects. Br J Surg 1993;80:834-842. |
| 113. |
Lai ECS, Mok FPT, Fan ST, Lo CM, Chu KM, Liu CL,
Wong J. Preoperative endoscopic drainage for malignant obstructive
jaundice. Br J Surg 1994;81:1195-1198. |
| 114. |
Lai ECS, Mok FPT, Tan ESY, Lo CM, Fan ST, You KT,
Wong J. Endoscopic biliary drainage for severe acute cholangitis. N
Engl J Med 1992;326:1582-1586. |
| 115. |
Jacyna MR, Summerfield JA. Endoscopic management
of biliary tract obstruction in the 1990s. J Hepatol
1992;14:127-132. |
| 116. |
Chijiiwa K, Kozaki N, Naito T, Kameoka N, Tanaka
M. Treatment of choice for choledocholithiasis in patients with
acute obstructive suppurative cholangitis and liver cirrhosis. Am J
Surg 1995;170:356-360. |
| 117. |
Freeman ML, Nelson DB, Sherman S, Haber GB, Herman
ME, Dorsher PJ, Moore JP, et al. Complications of endoscopic
biliary sphincterotomy. N Engl J Med 1996;335:909-918. |
| 118. |
Prat F, Tennenbaum R, Ponsot P, Altman C,
Pelletier G, Fritsch J, Choury AD, et al. Endoscopic sphincterotomy
in patients with cirrhosis. Gastrointest Endosc
1996;43:127-131. |
| 119. |
Schemel WH. Unexpected hepatic dysfunction found
by multiple laboratory screening. Anesth Analg (Cleve)
1976;55:810-812. |
| 120. |
Wataneeyawech M, Kelly KA Jr. Hepatic diseases
unsuspected before surgery. N Y State J Med 1975;75:1278-1281. |
| 121. |
Burroughs AK, Matthews K, Qadiri M, Thomas N,
Kernoff P, Tuddenham E, McIntyre N. Desmopressin and bleeding time
in patients with cirrhosis. Br Med J 1985;291:1377-1381. |
| 122. |
Fan S-T, Lo C-M, Lai ECS, Chu KM, Liu CL, Wong J.
Perioperative nutritional support in patients undergoing
hepatectomy for hepatocellular carcinoma. N Engl J Med
1994;331:1547-1552. |
| 123. |
Nompleggi DJ, Bonkovsky HL. Nutritional
supplementation in chronic liver disease: an analytical review.
HEPATOLOGY 1994;19:518-533. |
| 124. |
San-In Group of Liver Surgery. Long-term oral
administration of branched chain amino acids after curative
resection of hepatocellular carcinoma: a prospective randomized
trial. Br J Surg 1997;84:1525-1531 |
table Of Contents
Copyright © 1999 by the American Association for the Study
of Liver Diseases.
Hepatitis Central
http://hepatitis-central.com
|